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Abstract 51 
Introduction: Continuous cardiac afterload evaluation could represent a useful tool during 52 
general anesthesia (GA) to titrate vasopressor effect. Using beat to beat descending aortic 53 
pressure(P)/flow velocity(U) loop obtained from esophageal Doppler and femoral pressure 54 
signals might allow to track afterload changes. 55 
Methods: We defined 3 angles characterizing the PU loop (alpha, beta and Global After-Load 56 
Angle (GALA)). Augmentation index (AIx) and total arterial compliance (Ctot) were 57 
measured via radial tonometry. Peripheral Vascular Resistances (PVR) were also calculated. 58 
Twenty patients were recruited and classified into low and high cardiovascular (CV) risk 59 
group. Vasopressors were administered, when baseline mean arterial pressure (MAP) fell by 60 
20%.   61 
Results: We studied 118 pairs of pre/post bolus measurements. At baseline, patients in the 62 
lower CV risk group had higher cardiac output (6.1±1.7 vs 4.2±0.6 L/min; p = 0.005), higher 63 
Ctot (2.7±1.0 vs 2.0±0.4 ml/mmHg, p = 0.033), lower AIx and PVR (13±10 vs 32±11 % and 64 
1011±318 vs 1390±327 dyn.s.cm
-5
; p<0.001 and p=0.016, respectively) and lower GALA 65 
(41±15 vs 68±6°; p<0.001). GALA was the only PU Loop parameter associated with Ctot, 66 
AIx and PVR. After vasopressors, MAP increase was associated with a decrease in Ctot, an 67 
increase in AIx and PVR and an increase in alpha, beta and GALA (p<0.001 for all). Changes 68 
in GALA and Ctot after vasopressors were strongly associated (p=0.004). 69 
Conclusions: PU Loop assessment from routine invasive hemodynamic optimization 70 
management during GA and especially GALA parameter could monitor cardiac afterload 71 
continuously in anesthetized patients, and may help clinicians to titrate vasopressor therapy.  72 
Keywords : 73 
Blood Flow Velocity; Pressure; Ventricular Function, Left; Arteries; Compliance; Pulse 74 
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 75 
Introduction 76 
During General Anaesthesia (GA), prolonged hypotensive episodes have been 77 
associated with negative postoperative outcomes 
1,2
, such as myocardial infarctions 
3,4
, acute 78 
kidney injuries 
5
, or strokes 
6
. To this concern, American and European societies of 79 
anaesthesiology and intensive care have highlighted the importance of perioperative 80 
hemodynamic optimization strategies 
7,8
. This management requires understanding of 81 
hypotension’s aetiologies through hemodynamic monitoring, in order to titrate fluid and/or 82 
vasopressor therapies. Although it has been clearly established that fluid therapy should be 83 
titrated according to preload or stroke volume (SV) 
9–11
, monitoring of vasopressor effects is 84 
more challenging. Indeed, vasopressors (direct or indirect alpha-1 agonists) restore mean 85 
arterial pressure (MAP) by vasoconstriction but also increase cardiac afterload and wave 86 
reflections by reducing elastic properties of medium and small arteries. This could lead to 87 
undesirable side-effects in failing hearts 
12
. Vasopressors might increase oxygen cardiac 88 
consumption, reduce coronary perfusion pressure, and hence, be deleterious in cardiac 89 
diseases, in case of exaggerated increase of cardiac afterload 13. In such tight therapeutic 90 
context, it could be wise to continuously assess cardiac afterload in order to determine the 91 
best balance between beneficial and detrimental effects of vasopressors.  92 
Cardiac afterload evaluation remains complex during daily clinical practice. Indeed, as 93 
described by O Rourke et al.
14
, it includes the combination of three components: arterial 94 
compliance, aortic wave reflections and vascular resistances, all of which should be assessed 95 
separately using specific usually invasive tools. Analysis of central pressure waveforms has 96 
been used to monitor arterial function and properties during various vasodilatation states 
15,16
. 97 
Augmentation index (AIx), a parameter related to the amount of wave reflections occurring 98 
during systole and SEVR (subendocardial viability ratio), a measure of coronary perfusion, 99 
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have been related to cardiac workload and afterload. However, this type of analysis requires 100 
high fidelity ascending aortic pressure waveforms which are usually obtained via intra-aortic 101 
catheters or non-invasive tonometry. During routine GA, these technics are not practical: the 102 
invasive line usually rests on brachial or iliac artery where waveform morphology is altered 103 
and more difficult to interpret in terms of waveform analysis and cardiac afterload 
17,18
. We 104 
hypothesized that abdominal aortic pressure (P) coupled with flow waveform (U) into 105 
pressure-flow velocity (PU) loop diagram could allows a beat to beat assessment of cardiac 106 
afterload. We have conducted a pilot study to compare cardiac afterload parameters obtained 107 
from PU loops, with parameters obtained from central pressure analysis estimated by non-108 
invasive arterial tonometry. To this concern, we have assessed the changes of these 109 
parameters during GA, in high or low cardiovascular risks patients as well as before and after 110 
vasopressor administration.  111 
  112 
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Material and Methods 113 
This prospective observational study was performed on patients undergoing GA for 114 
neurosurgery. Between November 2013 and April 2014, the patients admitted at Lariboisiere 115 
University Hospital (Paris, France) for elective removal of intra-cranial tumours, or for 116 
intracranial aneurysm surgery, were screened for inclusion. Only patients in whom 117 
preoperative anesthesia’s consultation had indicated continuous arterial pressure through 118 
femoral puncture and cardiac output monitoring during the procedure, were eligible for the 119 
study. What is more, only patients who medically required vasopressors to maintain their 120 
MAP during the intervention were included in the study. Exclusion criteria were age < 18 121 
year, pregnancy or contraindication for the use of transesophageal Doppler. This study was 122 
approved by the Institutional Review Board of the « Société de Réanimation de Langue 123 
Française » (CE SRLF 11-356), that exempted signed informed consent. Every subject was 124 
orally informed for its inclusion in this study.  125 
Procedure 126 
GA was induced with total intravenous anesthesia using propofol (75-150 mg/kg/min) and 127 
remifentanil (0.2-0.5 µg/kg/min). Patients were intubated after administration of atracurium 128 
(0.5 mg/kg), and ventilation was set up until End Tidal CO2 reached 35 to 38 mmHg, with 129 
Tidal Volume of 6 and PEEP of 4 cmH2O. The arterial line was inserted via the femoral 130 
artery, using 4 French, 20 cm, catheter (Seldicath®, Prodimed, France). Pressure signals were 131 
recorded 20cm far from the puncture point so approximatively in the abdominal aorta above 132 
the iliac bifurcation. Signals were processed through a Philips MP60 monitor (Philips, NL) 133 
and a CombiQ monitor (Deltex Medical®, Chichester, UK). A trans-esophageal Doppler 134 
probe was used according to manufacturer recommendations (Deltex Medical®) to record 135 
flow velocity (U) at the level of the thoracic aorta. The CombiQ monitor was a specific 136 
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prototype allowing to record simultaneously and continuously arterial pressure and aortic 137 
velocity signals at a sampling frequency of 180Hz 138 
Ascending arterial pressure signal was estimated non-invasively using radial applanation 139 
tonometry (ShygmoCor, Atcor Medical, Sydney, Australia). A specific wristband 140 
Millartonometer was installed on the radial artery after the induction of anesthesia and kept in 141 
position during the whole procedure. Waveforms were calibrated using mean and diastolic 142 
iliac pressures obtained by invasive femoral catheterization. The standard commercial well-143 
validated generalized transfer function of SphygmoCor was used to estimate central 144 
waveforms. Only recordings with a quality index above 90% were used.  The SphygmoCor 145 
system then estimates cardiac afterload parameters such as central pulse pressure (CPP) and 146 
augmentation index (AIx) which represents the excess pressure due to the reflected waves. 147 
Total arterial compliance was calculated as Ctot = SV/CPP, where SV was the stroke volume 148 
given by the trans-esophageal Doppler monitor 
19–21
. Peripheral Vascular Resistance (PVR) 149 
was calculated using the modified Poiseuille equation: PVR (dyn.s.cm-5) = MAP (mmHg) / 150 
CO (l/min) * 80 
22
. 151 
Intervention 152 
Hypotensive episodes were defined the when MAP fell at least 20% under the pre anesthesia 153 
MAP  
23
. Following standard care protocol of our anesthesia department, when hypotension 154 
was identified as a consequence of sedative drugs, as a first line treatment, patients received 155 
250 ml sodium isochloride that could be followed by vasopressor as a second line therapy: a 156 
bolus dose for Ephedrine (9 mg), Norepinephrine (5 µg), or Phenylephrine (50 µg). For all 157 
other etiologic diagnoses, patients were treated according to physician’s choice.  158 
As each patient may have received several boluses of vasoconstrictors, only boluses 159 
administered to treat general anesthesia-induced arterial hypotension with following 160 
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characteristics were analyzed: (1) stable hemodynamic state with no acute change of MAP or 161 
CO 1 minute before bolus (2) no clear evidence of hypovolemia or acute hemorrhage, (3) no 162 
concomitant rapid fluid administration, (4) no change in respiratory or ventilator parameters 163 
or anesthesia infusion rate 3 minutes before or during bolus and (4) in case of multiple 164 
boluses in a short interval were administered, we analyzed only the first bolus if the delay 165 
between the first and the second boluses was more than 5 minutes to try to eliminate the 166 
confounding factors such as synergism between the drugs and repetitive boluses. 167 
 168 
Hemodynamic measurements: 169 
Hemodynamic recordings, including standard measurements, tonometer derived parameters, 170 
and PU loop assessments were started a few seconds before the anesthetist administered 171 
vasopressor and run for a few seconds after the mean arterial pressure started to decrease. The 172 
investigator identified the baseline as the period corresponding to the few second before the 173 
administration of the treatment. The peak effect sample was defined as the heart beat with the 174 
maximal mean arterial pressure following vasopressor administration. Each vasopressor 175 
administration was thus associated with a couple of baseline and peak assessment. 176 
PU Loop (Fig. 1) 177 
In order to plot PU loops: one pressure pulse and its simultaneous flow velocity pulse were 178 
manually selected. Only good visual quality pulses were used in the off-line analysis (Matlab, 179 
Mathworks, US). Due to equipment filtering and processing, there was a systematic delay 180 
between the 2 signals which could go up to 20ms. Pressure and flow velocity pulses were 181 
hence visually aligned using the upstroke of the pressure pulse (maximum of the 2
nd
 182 
derivative) and the point when flow becomes different from 0. PU loop were plotted for each 183 
subject before and at maximal vasopressor effect.  184 
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In order to characterize PU loops, we defined 4 characteristic points (Fig. 1):  185 
A: End Diastole: corresponding to the last point when flow in the aorta equals zero  186 
B point: corresponding to maximal velocity in the aorta 187 
C point: corresponding to maximal pressure in the aorta 188 
D point: End Systole when the flow in the aorta goes back to zero 189 
 190 
Fig. 2 and 3 present some examples of PU loops. The area covered by the loop did not 191 
properly described its shape as an “elongated” loop (such as in low risk patient) could have 192 
the same area than a more “rounded” loop (such as in high risk patient). Hence, to quantify 193 
the tilt and the opening of the loop, we defined 3 angles (Fig. 1B): 194 
- The Alpha angle representing the angle between the horizontal line and the AB line 195 
- The Beta angle representing the angle between the AB and AC lines. 196 
- The Global AfterLoad Angle (GALA) representing the angle between the horizontal and the 197 
AC lines (equal to the sum of alpha and beta angle). 198 
 199 
Statistical analysis 200 
Results are expressed as mean and standard deviation for continuous variables. Discontinuous 201 
variables are expressed in number and percentage.  202 
As arterial properties are known to differ according to patient cardiovascular (CV) risk, 203 
patients were separated into two groups depending on their number of CV risk factors. Risk 204 
factors taken into account were: age> 55 years old, arterial hypertension, current smoking, 205 
history of previous cardiovascular event, diabetes mellitus, dyslipidemia or congestive heart 206 
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failure. Patients with 0 or 1 CV risk factor constituted the “Low CV Risk” group, while the 207 
“High CV Risk” group was composed with patients with 2 or more CV risk factors. 208 
Patients’ characteristics were compared 1) between Low CV Risk and High CV Risk groups 209 
and 2) between Baseline and Peak effect of vasopressor. During GA, several vasopressor 210 
boluses might be administered. To take into account multiple measures per patients, 211 
hemodynamic measurement analysis was conducted using mixed effect models for repeated 212 
measures where the weight corresponded to the number of measurements per patients. 213 
Comparisons were performed using a weighted student test (for paired or unpaired variables).  214 
Meta regression was performed at baseline for static association assessment between 215 
parameters. Absolute difference between baseline and maximal effect of vasopressor was 216 
used for dynamic association assessment between parameters. Meta regression results were 217 
expressed as slope and 95% confidence interval. 218 
Microsoft Excel (Microsoft, US) and Matlab software (Mathworks, US) were used to plot and 219 
analyse PU loops. The Metafor package from the R project software (The R Foundation for 220 
Statistical Computing, Vienna, Austria) was used for meta regression analysis.  221 
  222 
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 223 
Results 224 
Patients’ main characteristics are presented in table 1 (n = 20). Eleven patients were in the 225 
low CV risk group and 9 in the high CV risk group. Low CV risk patients were younger and 226 
presented a lower ASA score compared to the high CV risk group. No patients suffered for 227 
heart failure. 228 
Hemodynamic profile of patients at baseline  229 
One hundred and eighteen PU loops were performed at baseline in the whole population, 230 
before any vasopressor administration. As expected, at baseline, high risk patients had higher 231 
Aix and PVR; and lower Ctot and CO (table 1) but, there was no statistical significant 232 
difference in MAP. Fig. 2A and 2B present examples of low and high risk patients’ PU loops.  233 
All defined angles - Alpha, Beta and GALA - were greater in the high risk group compared to 234 
the low risk group (56 ± 11° vs 36 ± 16 ° ; p=0.004, 7 ± 5° vs. 2 ± 3 ° ; p = 0.017, and 68 ± 6° 235 
vs. 41 ± 15 ° ; p<0.001, for alpha, beta and GALA angles respectively, table 1). 236 
When comparing PU Loop parameters, a negative association has been found between Ctot 237 
and GALA (Fig. 4). Indeed, GALA increased by 11.9 [3.8 - 20] °, for 1 ml/mmHg decrease in 238 
Ctot (p = 0.004). Furthermore, a positive association has been found between both GALA and 239 
Beta, and Aix: GALA increased by 8.8 [3.8 - 13.7] °, and Beta increased by 2 [0.7 - 3.2] °, for 240 
10 % increase in AIx (p < 0.001 and p = 0.002, respectively). We also found a positive 241 
association between PVR and both GALA and Beta: GALA increased by 2.2 [0.2 - 4.2] °, and 242 
Beta increased by 0.9 [0.2 - 1.5] °, for 100 dyn.s.cm-5 increase in PVR (p = 0.033 and p = 243 
0.006 respectively). 244 
 245 
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Assessment of dynamic alteration of cardiac afterload during vasopressors administration 246 
(table 2): 247 
One hundred and eighteen boluses of vasopressors were studied. In our population, 248 
vasopressor administration led to an increase in MAP, in Aix and in PVR (+18 ± 6 mmHg ; 249 
+4 ± 4% and ; +715 ± 357 dyn.s.cm
-5 
; respectively ; p < 0.001 for each), and to a decrease in 250 
CO and Ctot (-1.0 ± 0.9 L/min ; -0.8 ± 0.5 ml/mmHg, p<0.001 ; respectively). Fig. 3 shows 251 
changes in pressure, flow velocity and PU loop after vasopressor bolus. These changes 252 
occurred within a few heart beats (15 heart beats on patient presented on Fig. 3B). 253 
Vasopressors significantly increased GALA (+8 ± 4°, p < 0.001), as well as Alpha and Beta 254 
angles (p < 0.001). 255 
Vasopressor-induced increases in GALA were negatively associated with changes in Ctot (-256 
5.2 [-8.7 - -1.7] ° for 1ml/mmHg increase in Ctot, p = 0.004, Fig. 4), whereas no association 257 
was observed between changes in GALA, Alpha or Beta, and changes in Aix or PVR.  258 
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Discussion  259 
This study describes a method to define cardiac afterload parameters derived from 260 
aortic pressure – flow velocity (PU) loop plotted with standard hemodynamic signals, 261 
recorded during general anesthesia. These parameters: alpha, beta and the Global AfterLoad 262 
Angle (GALA) angles quantify the tilt and shape of the PU loop.   263 
Our study showed that those angles 1) varied adequately according to the presence of 264 
cardiovascular risk factors and 2) allowed us to track changes in afterload after vasopressor 265 
administration. 266 
Afterload is described as a combination of 3 constitutive components 
17
, acting 267 
together to counteract heart’s ejection forces: Arterial Stiffness, Aortic Reflection Waves and 268 
Arterial Resistances. In our study, we used AIx, Ctot and PVR calculation as estimates of 269 
these 3 cardiac afterload components. Indeed, even if general monitoring parameters such as 270 
MAP, CO and HR are of course available, their interpretation in terms of cardiac afterload is 271 
tricky, as they are fully interlinked and dependent on CV risk. The novelty of our approach is 272 
to propose a quantification of afterload during general anesthesia through a combined analysis 273 
of Pressure and flow using the angles of the PU loops. Our work aimed to describe a 274 
continuous and reactive method which could offer visual assessment of cardiac afterload, and 275 
guide anesthetist to dose vasoactive drugs. 276 
At a physiological point of view, a small GALA angle reflects a low afterload: cardiac 277 
ejection produces a high flow velocity for a relatively low pressure. On the opposite, a high 278 
GALA angle implies that a relatively low ejected volume ends up creating a high pressure 279 
pulse. Alpha angle could be more related to local wave velocity through the water hammer 280 
equation 
24
 and beta angle to wave reflections.  281 
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These interpretations corroborate the differences observed between low and high CV 282 
risk groups as regard to Alpha, Beta and GALA angles (table 1) as well as with the 283 
correlations found with Ctot, AIx and PVR (Fig. 4). Indeed, as expected and previously 284 
reported 
20,25–27
, AIx and PVR were higher and Ctot lower with high CV risk patients. They 285 
also have higher Alpha, Beta and GALA angles indicating higher cardiac afterload (table 1). 286 
Interestingly, GALA was the only parameter significantly associated with the 3 components 287 
of cardiac afterload (Fig. 4) while Beta showed a strong relationship with AIx. Those results, 288 
while encouraging, should be tempered by the classification used to separate population. 289 
Indeed, we used a non-validated classification based on the number of CV risks the patients 290 
expressed. While a stratification according to the surgical risk should be more intuitive in 291 
terms of post-operative outcomes, to our knowledge, no statistical score is especially designed 292 
to evaluate the arterial stiffness or the cardiac afterload. While ASA Classification or Revised 293 
Cardiac Index 
28,29
 could fit our clinical purposes, those score doesn’t integrate the age that is 294 
known to be the most influent factor in terms of cardiac afterload 
30
.  295 
After rapid pharmacological vasopressor bolus, AIx, Ctot and PVR were altered. As 296 
were the 3 novel angle parameters of the PU loop. However, the association between changes 297 
in AIx or PVR and changes in GALA did not reach statistical significance. This surprising 298 
result might be explained by the potential inaccuracy of the comparators. Indeed, while AIx 299 
has been shown to be a reliable marker during vasoactive challenges 
15,16
, those results have 300 
only been observed in a young population, free of CV risk factors. In older population, AIx 301 
might not be such a sensitive parameter 
31
. During physical exercise, a strong vasoactive 302 
stimulus, Thiebaud et al.
32
 have shown that AIx has only been linked to alteration of cardiac 303 
afterload in the youngest population. Unfortunately, our study is underpowered to analyze the 304 
effect of age on vasopressor agents’ effect. Another limitation could arise because 305 
15 
 
Sphygmocor system used to estimate central pressure has only been validated in awaken 306 
patients, under the scope of hypertension pathology, and not during general anesthesia. 307 
Interestingly, PVR did not show any association with PU loops angles during 308 
vasopressor agent administration. However, as discussed expansively by Nichols and 309 
O’Rourke 
17
, PVR can find a physiological meaning in terms of cardiac afterload only in 310 
steady flow conditions, ie at a distal level of the arterial tree, and not at the aortic level. Thus, 311 
our PU loop which is a dynamic, and beat by beat analysis of Pressure and Flow in Aorta, is 312 
probably not the most adequate algorithm to track changes in PVR.  313 
In our data, only decrease in Ctot has remained strongly associated with increase in 314 
GALA in response to vasopressor agents. Several comments can be addressed about this 315 
finding. First, in literature, data relating effects of vasopressors on total arterial compliance 316 
are very scarce. However, the SV on PP ratio has been shown to be reliably linked to decrease 317 
in cardiac afterload in a population of hypertensive patients taking daily calcium channel 318 
blocker 
33
.We hence used the SV on PP algorithm as an estimator of Total Arterial 319 
Compliance. Even if such a method has expressed poor agreement with the area method 320 
(more accurate measurement of Ctot) in dogs
34
, the correlation coefficient between the two 321 
algorithm were 0.78. Chemla et al. have also observed this finding in humans
20
. Finally, Ctot 322 
is thought to represent Windkessel model of arterial circulation and which is known to have 323 
some imperfection, but at a global arterial system point of view, this model is sufficient to 324 
explain arterial circulation observations 
35–37
.   325 
As mentioned above, central pressure analysis can be used as a surrogate of afterload 326 
38
, in particular to quantify vasoactive drug effects 
15
.  However high quality invasive central 327 
pressure recordings or estimated central waveforms from carotid or transformed radial 328 
applanation tonometry are not easily available during GA. We wanted a method to quantify 329 
16 
 
afterload based on GA routine care in order to be easily applicable. For this reason, we used 330 
flow velocity obtained by a trans-esophageal Doppler probe, and pressure waveforms 331 
recorded through fluid-catheters. One limitation of this approach could be the remoteness of 332 
the pressure measurement, at an arterial location slightly different from flow velocity point of 333 
measurement. Indeed, pressure wave shape and amplitude are greatly dependent on 334 
measurement site 
17,18
. This is the reason why we decided to select only patients with invasive 335 
femoral line in order to use pressures recorded as close as possible to flow recording point. 336 
However, femoral access for pressure measurement isn’t out of risk of complication, and 337 
should be used only for selected patients. This aspect limits the clinical application of our 338 
method. Nevertheless, improvement in technical aspect of PU loop could probably be done 339 
and work on the design of a specific transfer function from iliac and/or radial to aortic arch is 340 
currently in progress in our research unit. 341 
Another potential source of inaccuracy of our PU loops relates to the re-alignment of 342 
pressure and velocity waveforms. In our pilot study, this process was performed manually. An 343 
error of a few sample during the re-alignment might be possible. Swalen et al have studied the 344 
influence of the re-alignment on the PU loop
39
. While it can greatly modify the onset of PU 345 
loop and hence calculation of local wave speed, it however has little influence on the position 346 
of B and C and hence on the angles made by these points from the horizontal. 347 
Thiele et al. described a similar setting to ours but they used radial arterial catheter 348 
pressures that have been averaged to plot velocity-pressure loop. While their loop is inverted 349 
compared to the PU loop usually referred in the literature 
37,40
, their proposed setting brings, 350 
to our standpoint, additional drawbacks: 1) the use of radial pressure waveforms will alter the 351 
overall loop shape, 2) the use of average flow and pressure waveforms precludes analysis of 352 
acute afterload changes and, 3) to our experience,  area of the PU loop does not rendered 353 
correctly loop characteristics. Indeed, same surfaces can be found for PU loops of different 354 
17 
 
shapes. The novelty of our approach resides in the definition of alpha, beta and GALA angles 355 
which are simple sensitive parameters to describe the PU loop and its changes across CV risk 356 
and vasopressor drugs.  357 
This study was designed on a pragmatic approach based on routine procedures of 358 
standard neurosurgical cares including the use of vasopressors in non-hypovolemic patient to 359 
maintain cerebral perfusion. While our results support the feasibility of PU loop as a tool to 360 
monitor cardiac afterload, this pilot study only included 20 subjects preventing us to further 361 
evaluate the specific effect of the various vasopressors effects. Thus, further studies are 362 
required to confirm that GALA and GALA changes after vasopressor could be used to 363 
optimized perioperative hemodynamic strategies during GA during different volemic 364 
conditions.  365 
  366 
18 
 
Conclusion 367 
While our analysis was performed off-line, PU Loop assessment could potentially 368 
allow beat-to-beat quantitative analysis of cardiac afterload in clinical settings. This is 369 
achieved without any supplementary material, using signals already requested for 370 
hemodynamic optimization management in operating room and may help to better understand 371 
hemodynamics of high risk surgical patients during GA.  Further work on the use of the alpha, 372 
beta and GALA angle during GA in particular in patients with failing heart are however 373 
required. 374 
 375 
 376 
 377 
 378 
 379 
  380 
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Figures Legend 381 
Fig.1: Definition of analysis parameters  382 
Panel A: Example of synchronized arterial pressure and aortic flow velocity with the 383 
definition of augmentation index AIx and the A, B, C and D points as described in the 384 
methods section. 385 
 Panel B: Schematic representation of PU Loop with the 4 characteristics points and definition 386 
of the alpha, beta and Global AfterLoad Angles (GALA) 387 
 388 
Fig.2: Examples of pressure, flow and PU Loops at baseline (A and B) in low (A and B) and 389 
high (C and D) Cardio Vascular (CV) risk patients. 390 
 391 
Fig.3: Example of vasopressor effect of aortic pressure, aortic flow velocity and PU loop. 392 
Panel A: Example of aortic pressure (in black) and aortic flow velocity (in gray) before and at 393 
peak vasopressor effect. 394 
Panel B: beat to beat PU loops evolution from baseline (gray) to peak vasopressor effect 395 
(black) 396 
 397 
Fig.4: Association of GALA with AIx, Ctot and Peripheral Vascular Resistances (PVR) 398 
(Panel A.1-3, respectively), and changes of GALA after bolus versus change of AIx, change 399 
of Ctot and change of PVR (Panel B.1-3, respectively) 118 measurements were performed in 400 
20 patients. Each circle represents the weighted mean of repeated measure for one patient. 401 
The radius of the circle represents the number of measurements perform for each patient. 402 
(Slopes are expressed in ° per 1 ml/mmHg increase in Ctot, in ° per 10 % increase in AIx or in 403 
° per 100 dyn.s.cm-5 increase with their respective 95% interval confidence)   404 
 405 
 406 
407 
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Abbreviations 521 
AIx : Augmentation Index 522 
CPP : central pulse pressure 523 
Ctot : Total Arterial Compliance = SV/CPP 524 
CV risk:  Cardiovascular risk 525 
GA : general anesthesia 526 
GALA: Global After-Load Angle 527 
MAP : Mean arterial pressure 528 
P : Aortic pressure  529 
PU loop: pressure/flow velocity loop 530 
PVR  : Peripheral Vascular Resistances   531 
SV :  Stroke Volume 532 
U :  Flow velocity 533 
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